A FLASH of Insight: Breakthrough reveals that ultra-short, high-dose proton irradiation enhances cell survival
en-GBde-DEes-ESfr-FR

A FLASH of Insight: Breakthrough reveals that ultra-short, high-dose proton irradiation enhances cell survival

21/10/2024 Osaka University

A research group led by Osaka University has demonstrated for the first time in the world that a newly-developed accelerator achieved high-dose proton irradiation instantaneously, opening the door for radiation therapy with fewer symptoms

Osaka, Japan - Proton beam therapy, a type of radiation therapy, possesses a physical property known as the Bragg peak, which causes the beam to exert its strongest effect at a specific depth, with no effect beyond that point. This characteristic allows for a higher concentration of the dose on tumors located deep within the body, making it a promising cancer treatment method.

However, in some cases, the dose limit to surrounding healthy tissue necessitates a compromise in the tumor's radiation dosage or may even cause proton beam therapy to have to be abandoned altogether. Therefore, developing irradiation technologies that can further reduce the dose to normal tissues is a pressing issue.

In recent years, it has been reported that in radiation therapy, when the dose rate (the amount of radiation delivered per unit time) is extremely high, specifically more than 400 times the normal dose rate, a phenomenon occurs in which cell survival rate is increased, minimizing damage to normal tissues while maintaining local control of the tumor. This phenomenon, which results from the instantaneous delivery of radiation, is called the "FLASH effect" and has gained global attention.

Until recently, it was believed that increased cell survival rates with ultra-short proton beam irradiations only occurred under hypoxic conditions, as it had not yet been demonstrated whether cell survival rates increase with ultra-short proton irradiation under normal oxygen conditions.

However, a team of researchers from Kazuhiko Ogawa’s laboratory led by Osaka University was the first in the world to demonstrate that cell survival rates increase even under normoxic conditions with ultra-short irradiation by using Sumitomo Heavy Industries' new superconducting AVF cyclotron, which enables ultra-short, high-dose proton irradiation.

"There are very few experimental devices worldwide that can perform ultra-high dose rate irradiation, which made securing the necessary irradiation environment a significant challenge," says lead author Masashi Yagi. "The FLASH effect is a game-changer in radiation therapy, and unraveling its mechanisms will greatly advance the field of radiological science," says corresponding author Kazumasa Minami.

This research deepens the understanding of the mechanisms behind the FLASH effect and is expected to lead to the development of a cancer treatment method, known as FLASH proton therapy, that produces fewer side effects. FLASH proton therapy combines the physical characteristics of proton beams, which allow for high dose concentration on tumors, with the biological effects of the FLASH effect, which reduces damage to normal tissues. This synergy is anticipated to result in higher local control rates and lower side effect incidences than ever before.

“Our research group will continue to push forward with this work, contributing a new chapter to the 130-year history of radiation therapy from Japan as we strive to develop better radiation treatment methods." says senior author Shinichi Shimizu.

###

The article, “Sparing Effect on Cell Survival Under Normoxia Using Ultra-high Dose Rate Proton Beams from a Compact Superconducting AVF Cyclotron,” was published in Anticancer Research at DOI: https://doi.org/10.21873/anticanres.17255
Title: Sparing Effect on Cell Survival Under Normoxia Using Ultra-high Dose Rate Proton Beams from a Compact Superconducting AVF Cyclotron
Journal: Anticancer Research
Authors: Masashi Yagi, Kazumasa Minami, Kazuki Fujita, Shinji Nomura, Nagaaki Kamiguchi, Kana Nagata, Ryo Hidani, Daizo Amano, Kenzo Sasai, Shinichi Shimizu, Kazuhiko Ogawa
DOI: 10.21873/anticanres.17255
Funded by: Japan Society for the Promotion of Science
Attached files
  • Fig. Comparison of cell surviving fraction. At the same dose (20 Gy), the ultra-high dose rate (uHDR, green) had more surviving cells than the normal dose rate (NDR, purple) demonstrating the sparing effect. (A) Tumor cells. (B) Normal cells., Original content, No restrictions, Masashi Yagi
21/10/2024 Osaka University
Regions: Asia, Japan
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of news releases posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
  • iesResearch
Copyright 2024 by AlphaGalileo Terms Of Use Privacy Statement